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Papua New Guineaa b s t r a c t
Background: Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine
(PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated car-
riage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and
serotype diversity. This study investigated PCV13 impact on serotype-specific pneumococcal carriage
prevalence, density, and serotype diversity in PNG infants, who have some of the highest reported rates
of pneumococcal carriage and disease in the world.
Methods: Nasopharyngeal swabs were collected at 1, 4 and 9 months of age from PCV13-vaccinated
infants (n = 57) and age-/season-matched, unvaccinated infants (at approximately 1 month, n = 53; 4
months, n = 57; 9 months, n = 52). Serotype-specific pneumococcal carriage density and antimicrobial
resistance genes were identified by qPCR and microarray.
Results: Pneumococci were present in 89% of swabs, with 60 different serotypes and four non-
encapsulated variants detected. Multiple serotype carriage was common (47% of swabs). Vaccine type
carriage prevalence was similar between PCV13-vaccinated and unvaccinated infants at 4 and 9 months
of age. The prevalence of non-vaccine type carriage was also similar between cohorts, with non-vaccine
types present in three-quarters of samples (from both vaccinated and unvaccinated infants) by 4 months
of age. The median pneumococcal carriage density was high and similar at each age group (~7.0 log10 -
genome equivalents/mL). PCV13 had no effect on overall pneumococcal carriage density, vaccine type
density, non-vaccine type density, or the prevalence of antimicrobial resistance genes.








K.J. Britton, J.L. Pickering, W.S. Pomat et al. Vaccine xxx (xxxx) xxxserotypes from 1 month of age. PCV13 had no impact on pneumococcal carriage density, even for vaccine
serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density and abundance
of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in PNG infants. Indirect
effects of the infant PCV programs are likely to be limited in PNG. Alternative vaccines with broader cov-
erage should be considered.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Streptococcus pneumoniae (the pneumococcus) is a common
nasopharyngeal commensal and pathogen, causing a range of
major diseases including pneumonia, otitis media, meningitis and
sepsis. Nasopharyngeal carriage of the pneumococcus is a precur-
sor for disease, and children are the primary reservoir for transmis-
sion. The polysaccharide capsule of the pneumococcus is a key
virulence factor, with over 100 capsular serotypes identified to
date [1]. This capsule induces protective antibodies that forms
the basis for pneumococcal conjugate vaccines (PCVs), including
the currently licensed 10-valent (PCV10) and 13-valent (PCV13)
vaccines [2].
Globally, PCVs have been highly effective in reducing carriage
and disease caused by the pneumococcal serotypes they contain
(vaccine serotypes) [3]. The introduction of PCVs has also been
shown to reduce antimicrobial resistance (AMR) associated with
pneumococcal disease, as vaccine serotypes commonly contain
antibiotic resistance determinants [4]. However, as PCVs have been
introduced, serotype replacement has been observed with non-
vaccine serotypes replacing vaccine serotypes, and in some set-
tings (especially high-risk) minimal impact on the overall rates of
pneumococcal carriage and disease has been reported [5]. Serotype
replacement is of particular concern in low-income populations as
there is often higher prevalence, density and diversity of pneumo-
coccal carriage and higher rates of pneumococcal disease [6]. The
threat is even greater when the emerging non-vaccine serotypes
are highly invasive and/or associated with antibiotic resistance,
for example the observed global increase in serotype 19A, which
is often antibiotic-resistant, following widespread introduction of
the 7-valent PCV (PCV7) [7,8].
Papua New Guinea (PNG) has some of the highest reported rates
of childhood pneumococcal carriage and disease in the world. PNG
infants are colonised with a broad range of serotypes within weeks
of birth: at least 60 different serotypes were identified in the
nasopharynx of healthy children under 2 years [9)], and children
under 5 years with pneumococcal pneumonia [10]. The Global Alli-
ance for Vaccines and Immunisation (Gavi) and the World Health
Organization assisted introduction of PCV13 in PNG in 2014. How-
ever, the extreme pneumococcal diversity within the nasopharynx
of PNG children means that currently available PCVs are limited in
their ability to provide protection against pneumococcal carriage
and thus potentially disease [9]. We do not fully understand the
impact of PCVs in populations such as PNG that experience early,
dense and diverse pneumococcal carriage; and the impact of
PCV13 on vaccine and non-vaccine serotype density and diversity
in such a setting has not, to our knowledge, been assessed before.
Semi-quantitative colonisation data from a PCV7 study in The
Gambia, with a lower pneumococcal carriage frequency than
PNG children, reported no difference in pneumococcal carriage
density post-PCV7 for vaccine types and non-vaccine types [11].
In addition, a PCV7 study in Peru (also with lower carriage rates
than PNG children) found no overall change in pneumococcal car-
riage density post-PCV7 introduction, though serotype-specific
carriage densities were not measured [12]. Information on the2
effect of PCVs on pneumococcal carriage density in different popu-
lations is important for assessing PCV effectiveness. High pneumo-
coccal carriage density, as observed in young children especially in
lower-middle income countries and Indigenous populations
throughout the world is thought to be a major contributing factor
to high rates of pneumococcal disease. Vaccines that can reduce
the pneumococcal load and thus transmission rate are therefore
more likely to elicit herd immunity. Understanding PCV13 impact
on vaccine and non-vaccine type carriage in a high-risk setting
such as PNG is an important measure of PCV effectiveness, with
data informing future requirements of pneumococcal vaccines
and associated programs, particularly for populations with dense
and diverse pneumococcal carriage.
The specific objective of this study was to compare vaccine and
non-vaccine serotype carriage density in PCV13-vaccinated and
unvaccinated Papua New Guinean infants. We hypothesised that
the carriage density of vaccine serotypes would be reduced, and
the density of non-vaccine serotypes would increase in the
nasopharynx of PCV13-vaccinated children compared to age-
matched unvaccinated children.2. Materials and methods
2.1. Setting
This study was conducted in the Eastern Highlands Province
(EHP) of PNG. PNG is a lower-middle income country situated in
the south-west Pacific, with a population of over eight million
[13]. Pneumonia is the leading cause of paediatric hospital admis-
sion nationally. It is particularly prevalent in the EHP, where pneu-
monia accounts for 30-40% of hospitalisations [14]. Located within
Goroka, the capital of the EHP, are the Eastern Highlands Provincial
Hospital (the sole tertiary healthcare facility in the province) and
the PNG Institute of Medical Research (PNGIMR). Living standards
vary widely between urban and rural areas of the EHP, with many
villages only accessible by foot or 4-wheel drive [15]. Since 2014,
the national immunisation program for PNG infants has included
PCV13, with recommended administration at 1, 2 and 3 months
of age. However, the vaccine was not available in the study area
until the following year, and by late 2015, first and third dose cov-
erage was only around 25% and 5% respectively [16].
2.2. Study design and participant selection
Nasopharyngeal swabs were collected from participants
enrolled in two studies carried out at PNGIMR: the 10v13v PCV
trial, and the PNG pneumonia and meningitis aetiology study.
The design and methods for these studies have been described
elsewhere [15,16]. Briefly, the 10v13v PCV trial was an open
randomised-controlled trial, conducted between 2011 and 2016,
to determine the safety and immunogenicity of PCV10 and
PCV13 and 23-valent pneumococcal polysaccharide (23vPPV)
booster. Participants were randomly allocated to receive either
PCV at ages 1, 2 and 3 months with or without a PPV23 booster
at 9 months of age. Pneumonia episodes were identified by passive
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4, 9, 10, 23 and 24 months of age to assess pneumococcal colonisa-
tion, with 1-month swabs collected prior to the first dose of PCV13
[15]. For the present study, 1-, 4- and 9-month swabs were
included.
The PNG pneumonia and meningitis aetiology study was a
prospective case-control study conducted between 2013 and
2016, that enrolled children under 5 years of age to determine
the aetiology of clinically defined moderate or severe pneumonia
or suspected meningitis. Cases were identified following presenta-Fig. 1. Development of the analytical cohort. NPS, number of nasopharyngeal swabs col
selected for microarray was based on funding limitations, selection was at random;
matched ± 1 month, 9-month nasopharyngeal swabs were age-matched ± 2 months; c
gentamicin and incubated for 18–24 h (4). Four nasopharyngeal swabs were lytA positive
these samples were not included in prevalence and density analyses. The 10v13v PCV t
3
tion for inpatient or outpatient care in Goroka town. Controls were
healthy children recruited contemporaneously from cases’ com-
munities. Following enrolment, immunisation history and diagnos-
tic specimens, including nasopharyngeal swabs, were obtained
from both cases and controls [16].
The selection of participants from these two cohorts is depicted
in Fig. 1. From the 10v13v PCV trial (hereafter referred to as the
PCV13 cohort), 57 infants were identified that were vaccinated with
3 doses of PCV13 and had nasopharyngeal swabs collected at 1, 4
and 9 months of age. The resulting 171 nasopharyngeal swabslected; PCV13, 13-valent pneumococcal conjugate vaccine; a number of specimens
b in the unvaccinated cohort, 1- and 4-month nasopharyngeal swabs were age-
dilutions of swab sample aliquots were placed onto horse blood agar plates with
and culture-positive, however no pneumococcus was detected by microarray, thus
rial was a longitudinal study, participants were swabbed at multiple timepoints.
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geal swabs from 162 unvaccinated children that were controls in
the cross-sectional PNG pneumonia and meningitis aetiology study
(hereafter referred to as the unvaccinated cohort), with one swab
collected per participant at ages 0-2, 3-5, or 7-11 months (n = 53,
57 and 52, respectively). This resulted in a total of 333 nasopharyn-
geal swabs for analysis.
2.3. Specimen collection and processing
Nasopharyngeal swabs were collected, transported and stored
at PNGIMR in accordance with the WHO guidelines [15,17], and
then cryogenically shipped to the Telethon Kids Institute in Perth,
Australia for pneumococcal quantification.
2.4. Pneumococcal detection and microarray analysis
Real-time quantitative-polymerase chain reaction (qPCR) tar-
geting the lytA gene was undertaken on all 333 nasopharyngeal
swabs [18]. A cycle threshold value of <30 was considered positive.
Pneumococcal positive nasopharyngeal swabs (n = 301) were
transported to the Murdoch Children’s Research Institute in Mel-
bourne, Australia, for pneumococcal enrichment and molecular
serotyping by microarray as described previously [4]. In brief,
nasopharyngeal swabs were cultured on horse blood agar contain-
ing 5 mg/mL of gentamicin, and DNA extracted from the bacterial
growth with the QIAcube HT instrument (Qiagen). Molecular
serotyping was conducted using Senti-SP v1.5 microarray (BUGS
Bioscience), which reports the identity and relative abundance
(%) of all pneumococcal serotypes detected within a sample. The
microarray can also detect 10 AMR genes associated with mobile
genetic elements (tetM, tetK, tetO, tetL, cat, aphA3, sat4, mefA, ermB
and ermC). Pneumococcal carriage was defined as detection of any
pneumococci, including non-encapsulated lineages, in the
nasopharyngeal swabs.
PCV10 serotypes were defined as those serotypes contained in
PCV10 (1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19F and 23F). PCV13 serotypes
include those serotypes contained in PCV10, plus serotypes 3, 6A
and 19A. Non-encapsulated pneumococci (NT2, NT4a, NT4b, NT2/
NT3b) were categorised based upon previously described genetic
variants [2]. All remaining serotypes were defined as non-PCV13
serotypes (excluding non-encapsulated pneumococci). For exam-
ple, a swab containing both a PCV13 serotype and a non-PCV13
serotype, was considered positive for both PCV13 and non-PCV13
serotype carriage. Serotypes 15B and 15C were reported as 15B/C
as these serotypes are known to interconvert [19]. Pneumococci
that typed as ‘‘-like” by microarray were tested phenotypically (la-
tex agglutination and/or Quellung). Specifically, 23B-like serotyped
as 23B, 19A-like serotyped as 19F [20], and 11F-like serotyped as
11A [21]. Genetic variants that could not be resolved phenotypi-
cally were reported as per the microarray result.
Overall pneumococcal density (from lytA qPCR) was determined
for pneumococcal positive samples and reported in genome equiv-
alents/mL (GE/mL). Serotype-specific density was calculated by
multiplying overall pneumococcal density by the serotype relative
abundance (determined by microarray) [22].
2.5. Statistical analyses
Categorical data were summarised as counts and percentages,
and compared using the Pearson Chi-Square test, or Fisher’s Exact
test. Continuous data were summarised as medians and interquar-
tile ranges (IQR) and compared using the Mann-Whitney U test for
non-parametric data, except where indicated. A p value of  0.05
was considered significant. Pneumococcal density data were log10
transformed prior to analysis. Samples that were pneumococcal4
positive with unknown serotype (lytA positive, culture negative
samples were not able to proceed to microarray) were excluded
from analyses of serotype-specific pneumococcal carriage preva-
lence. Analyses of overall pneumococcal density were restricted
to samples that were positive for pneumococcal carriage, and anal-
yses of serotype-specific pneumococcal density and AMR genes
were restricted to samples that were pneumococcal positive by
microarray. Serotype diversity was assessed by calculating Shan-
non’s diversity index for the PCV13 and unvaccinated cohorts at
each timepoint. Data were cleaned and analysed in SPSS version
26 (IBM Corp, New York, NY, US). Graphs were created using
GraphPad Prism version 8 (GraphPad Software, La Jolla, CA, USA).
2.6. Ethics statement
Ethical approvals for this study were obtained from the PNGIMR
Institutional Review Board (IRB no. 1028) and the Government of
PNG Medical Research Advisory Committee (MRAC no. 11.03).
Samples from the PNG pneumonia and meningitis aetiology study
were collected under the following ethics approvals: IRB no. 1204,
MRAC no. 11.29 and The University of Western Australia
RA/4/1/7960. Samples from the 10v13v PCV trial were collected
under the following ethics approvals: IRB no. 1028 and MRAC no.
11.03. The 10v13v PCV trial is registered with ClinicalTrials.gov
(CTN NCT01619462).3. Results
3.1. Participant characteristics
Characteristics are shown in Table 1. There were 219 partici-
pants included in this study: 57 infants in the PCV13 cohort (with
swabs collected at 1, 4, and 9 months of age; 171 swabs), and 162
infants in the cross-sectional unvaccinated cohort (53, 57 and 52
children for each age group; 162 swabs). The median age at swab
collection for the 1-, 4-, and 9-month sample time-points was dif-
ferent between the cohorts, with the unvaccinated cohort ~2 weeks
older at the 1-month and 4-month time-point and 3 weeks older at
the 9-month timepoint. This was because the range for age at sam-
ple collection was relaxed in the unvaccinated cohort to allow for
season matching of samples to compensate for the differences in
year of sample collection. While the years over which swabs were
collected overlap between the cohorts, they are not entirely the
same (2011 to 2014 for the PCV13 cohort vs 2013 to 2016 for
the unvaccinated cohort); therefore, specimens from the cross-
sectional unvaccinated cohort were season-matched with the
PCV13 swab collection to ensure even collection across seasons
(by quarters) between the two groups (p = 0.893). Of the 57 infants
in the PCV13 cohort, 28.1% (n = 16) had at least one episode of
clinically-defined moderate or severe pneumonia in their first year
of life [23]. Preceding clinical data was not collected for children
recruited to the cross-sectional unvaccinated cohort.
3.2. Carriage prevalence
The overall pneumococcal carriage prevalence at 1 month of age
was 80% (with 78.9% pneumococcus-positive in the PCV13 cohort
and 81.1% in the unvaccinated cohort, Table 2a). Pneumococcal
carriage prevalence continued to increase by 4 months and
9 months of age, irrespective of PCV13-vaccination status. By
9 months of age, pneumococcal carriage was detected in 94.7% of
children in the PCV13 cohort and 92.3% in the unvaccinated cohort.
Table 2b shows the carriage prevalence of vaccine serotypes, non-
vaccine serotypes, and non-encapsulated pneumococci, by cohort
and age. PCV13 serotype carriage prevalence was similar between
Table 1
Characteristics of the study cohorts.
Characteristic Cohort p valuea
PCV13b Unvaccinated
Number of individuals sampled 57 162
Female sex, n (%) 31 (54.4) 80 (49.4) 0.541
Number of NPS collected 171 162
Median age in months at NPS collection (IQR)
1 month 1.02 (0.9–1.0) 1.45 (1.0–2.2) <0.001
4 months 4.04 (3.9–4.1) 4.47 (3.5–5.3) 0.041
9 months 9.03 (9.0–9.1) 9.75 (8.5–11.2) 0.003
Year of NPS collection: n (%)
2011 4 (2.3) –
2012 83 (48.5) –
2013 75 (43.9) 63 (38.9)
2014 9 (5.3) 67 (41.4)
2015 – 32 (19.8)
Quarter of NPS collection: n (%) 0.893
January - March 43 (25.1) 37 (22.8)
April - June 38 (22.2) 37 (22.8)
July - September 44 (25.7) 39 (24.1)
October - December 46 (26.9) 49 (30.2)
PCV13, 13-valent pneumococcal conjugate vaccine; NPS, nasopharyngeal swab; IQR, interquartile range; ap values compare between cohorts using Pearson chi-square test for
categorical data and Mann-Whitney U test for continuous data; bPCV13 cohort received three doses of PCV13 at 1, 2 and 3 months of age.
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9 months of age (35.1% vs 49.1%, p = 0.129 and 38.6% vs 44.2%,
p = 0.551, respectively). Non-vaccine type carriage prevalence
was also similar between the PCV13 cohort and the unvaccinated
cohort at 4 months and 9 months of age (75.4% vs 66.7%,
p = 0.302 and 73.7% vs 71.2%, p = 0.768, respectively).
Of the 301 lytA-positive samples, 4.3% (n = 13) were culture-
negative and therefore not serotyped. The non-encapsulated lin-
eage NT2, and serotypes 15B/C, 6A, 6B, 19F and 23F were the most
common. A complete list of all identified pneumococcal serotypes
is shown in Supplementary Table 1, where 60 capsular serotypes
and four non-encapsulated lineages were detected.
3.3. Pneumococcal carriage density
Pneumococcal carriage density detected in the nasopharyngeal
swabs ranged from 3.76 to 9.73 log10 GE/mL, with a median of 6.98
log10 GE/mL. The median pneumococcal carriage density did not
change with age or PCV13 vaccination status (Fig. 2, Table 3a).
There was also no difference in the carriage density of vaccine
types and non-vaccine types between the PCV13 cohort and the
unvaccinated cohort for each age (Table 3b). Carriage densities
for each serotype are shown in Supplementary Table 1, where
the carriage density of individual serotypes was similar between
cohorts. The high diversity of serotypes present in the nasopharynx
of these children means that numbers were too small to conduct
further statistical analyses.
3.4. Concurrent carriage of pneumococcal serotypes
Carriage of multiple serotypes (including non-encapsulated)
was common, with  2 types identified in 47.2% (n = 133) ofTable 2a
Comparing pneumococcal nasopharyngeal carriage prevalence by cohort at age 1, 4 and 9















Pneumococcal carriage (any) 45 (78.9) 43 (81.1) 0.775 51 (89
5
swabs: 69.2% with two types, 27.1% with three, 3.0% with four
and 0.8% with five different types identified in a single swab. Over-
all, there were no significant differences in the prevalence of mul-
tiple serotype carriage observed between cohorts. By timepoint,
co-colonisation was observed in 21.4% of the PCV13 cohort and
32.4% of the unvaccinated cohort at 1 month of age (p = 0.269),
63.3% of the PCV13 cohort and 44.4% of the unvaccinated cohort
at 4 months (p = 0.056), and 56.6% of the PCV13 cohort and
57.4% of the unvaccinated cohort at 9 months of age (p = 0.932).
There was a small increase in median overall pneumococcal den-
sity as the number of serotypes detected in a sample increased,
however the Kruskal Wallis test showed this did not reach statisti-
cal significance (6.93 log10 GE/mL, 7.01 log10 GE/mL, 7.24 log10 GE/
mL, 7.57 log10 GE/mL and 7.63 log10 GE/mL in samples with one,
two, three, four and five serotypes, respectively; p = 0.240).3.5. Diversity of pneumococcal serotypes
Serotype diversity was assessed by calculating Shannon’s diver-
sity index for the PCV13 and unvaccinated cohorts at each time-
point, whereby 0 indicates low diversity (dominated by one
serotype) and 1 indicates high diversity. We found the range of ser-
otypes detected to be highly and equally diverse between cohorts
and timepoints: 0.94, 0.93 and 0.94 at 1, 4 and 9 months respec-
tively in the PCV13 cohort; and 0.96, 0.94, and 0.94 at 1, 4 and 9
months respectively in the unvaccinated cohort. Serotype carriage
within individuals was also found to be highly variable and unsta-
ble over time. Of the 44 infants from the PCV13 cohort that carried
pneumococci at all three timepoints, 56.8% (n = 25) carried the
same serotype on a subsequent sample, and only 6.8% (n = 3) car-
ried the same serotype on all three samples.months.



















.5) 56 (98.2) 0.051 54 (94.7) 48 (92.3) 0.605
Table 2b
Comparing pneumococcal vaccine and non-vaccine type nasopharyngeal carriage prevalence by cohort at age 1, 4 and 9 months.
































Any PCV13-type 17 (30.9) 14 (29.2) 0.847 20 (36.4) 28 (50.9) 0.124 22 (39.3) 23 (45.1) 0.543
Any PCV10-type 13 (23.6) 10 (20.8) 0.733 16 (29.1) 19 (34.5) 0.539 13 (23.2) 16 (31.4) 0.343
1 - 1 (2.1) - - 1 (1.8) -
4 2 (3.6) 2 (4.2) – 1 (1.8) – 1 (2.0)
5 – – – – – 1 (2.0)
6B 1 (1.8) 2 (4.2) 3 (5.5) 5 (9.1) 4 (7.1) 5 (9.8)
7F 1 (1.8) – – – – –
9V – – – 1 (1.8) – –
14 2 (3.6) 1 (2.1) 5 (9.1) 3 (5.5) 5 (8.9) 3 (5.9)
18C – 1 (2.1) 2 (3.6) 1 (1.8) – 2 (3.9)
19F 3 (5.5) – 4 (7.3) 5 (9.1) 4 (7.1) 4 (7.8)
23F 4 (7.3) 3 (6.3) 4 (7.3) 4 (7.3) 2 (3.6) 3 (5.9)
Extra PCV13 types 5 (9.1) 5 (10.4) 1.000 6 (10.9) 11 (20.0) 0.187 10 (17.9) 9 (17.6) 0.977
3 2 (3.6) 1 (2.1) – – 1 (1.8) 1 (2.0)
6A 2 (3.6) 3 (6.3) 5 (9.1) 6 (10.9) 2 (3.6) 5 (9.8)




30 (54.5) 31 (64.6) 0.301 43 (78.2) 38 (69.1) 0.279 42 (75.0) 37 (72.5) 0.773
Non-PCV13
serotypes
21 (38.2) 28 (58.3) 0.041 39 (70.9) 34 (61.8) 0.313 40 (71.4) 34 (66.7) 0.594
Non-encapsulated 9 (16.4) 7 (14.6) 0.803 12 (21.8) 9 (16.4) 0.467 6 (10.7) 8 (15.7) 0.446
PCV13, 13-valent pneumococcal conjugate vaccine; aPCV13 cohort received three doses of PCV13 at 1, 2 and 3 months of age, 1-month nasopharyngeal swabs were collected
prior to the first dose of vaccine; bPearson chi-square test was used to compare PCV13 and unvaccinated cohorts; cincludes non-encapsulated and non-PCV13 serotypes.
Samples that were pneumococcal positive with unknown serotype (lytA positive, culture negative samples were not able to proceed to microarray) were excluded from
analyses of serotype-specific pneumococcal carriage prevalence.
Fig. 2. Pneumococcal carriage densities at 1, 4 and 9 months of age. Violin plots of
overall pneumococcal carriage densities (in log10 genome equivalents (GE)/mL) by
cohort in infants aged 1, 4 and 9 months. Dashed lines indicate median densities,
dotted lines indicate quartiles, and the density plot width indicates the frequency of
observations. The PCV13 cohort received three doses of PCV13 at 1, 2 and 3 months
of age; 1-month nasopharyngeal swabs were collected prior to the first dose of
vaccine.
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AMR genes were identified in 19% (n = 54) of pneumococcal
positive samples: 18.4% from the PCV13 cohort versus 16.7% from
the unvaccinated cohort at 4 months (p = 0.820); and 11.3% in the
PCV13 cohort versus 12.8% in the unvaccinated cohort at 9 months
(p = 0.824; Supplementary Table 2). The most frequently detected
AMR gene was tetM which encodes resistance to tetracycline.
There were no significance differences in the prevalence of the
ten AMR genes assessed, between cohorts at any age.6
4. Discussion
This study found that PCV13 had no impact on pneumococcal
carriage prevalence, carriage density or serotype diversity in Papua
New Guinean infants. By 1 month of age, 80% of infants were colo-
nised with the pneumococcus, prior to eligibility for their first dose
of PCV13. Following three doses of PCV13 at 1-2-3-months of age,
pneumococcal carriage prevalence increased to 89–95%, showing
no effect of vaccination on overall carriage in this study population.
The carriage rates are the highest reported in the literature, where
studies in endemic settings such as Kenya, The Gambia, and a refu-
gee camp in Thailand, report a maximum prevalence of pneumo-
coccal carriage of 63–80% at 3 months of age [11,24,25]. Our
study also demonstrates higher carriage prevalence, and at an ear-
lier age, than a previous study conducted in 2005 to 2009 in the
same area of PNG, which reported 59% (n = 152) of infants carrying
S. pneumoniae at 1 month of age, although this was only deter-
mined using culture-based techniques [9].
The non-encapsulated lineage NT2, and serotypes 15B/C, 6A, 6B,
19F and 23F were the most common types detected in our study.
At least one of these six types were detected in 46% (n = 155) of
all samples. Serotypes 6B, 19F, 23F, 15B/C and non-encapsulated
lineage NT2 were also amongst the most frequently reported car-
riage serotypes in infants in Indonesia and Fiji prior to PCV intro-
duction [22,26].
The persistent carriage of PCV13 serotypes in PCV13-vaccinated
infants (36% and 39% prevalence at one and six months post-
vaccination, respectively) is an important observation from this
study. There was some evidence of a reduction in carriage preva-
lence of PCV13 vaccine types in the vaccinated cohort (compared
to the unvaccinated cohort) at 4 months of age, however this
was not sustained to 9 months. This finding suggests that PCV13
does not have the same effect on prevention of vaccine type car-
riage as observed in other populations with lower densities and
Table 3a
Overall pneumococcal carriage density (in log10 genome equivalents/mL) by cohort in infants aged 1, 4 and 9 months.
















































Serotype-specific pneumococcal carriage densities (in log10 genome equivalents/mL) by cohort in infants aged 1, 4 and 9 months.











































































PCV13, 13-valent pneumococcal conjugate vaccine; IQR, interquartile range; aPCV13 cohort received three doses of PCV13 at 1, 2 and 3 months of age, 1-month nasopha-
ryngeal swab collected prior to first dose of vaccine; bMann-Whitney U test used to compare unvaccinated and PCV13 cohorts. Analyses of overall pneumococcal density were
restricted to samples that were positive for pneumococcal carriage, and analyses of serotype-specific pneumococcal density were restricted to samples that were pneu-
mococcal positive by microarray.
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PCV13 serotypes in a PCV13-vaccinated population it is unlikely
that pneumococcal transmission will be prevented, and thus vacci-
nating infants will have limited impact on pneumococcal disease in
unvaccinated children and adults. Of further concern, non-vaccine
types were present in three-quarters of samples (from both vacci-
nated and unvaccinated infants) by 4 months of age. Considering
the wide diversity of pneumococci detected in this population,
and the propensity for infants to carry up to five serotypes at one
time, it is unlikely that limited valency PCVs will be able to offer
the desired protection against overall pneumococcal disease. For
example, the recently FDA-approved 20-valent PCV (containing
PCV13 components plus CRM197-conjugated polysaccharide from
serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F) would cover 44.3% of
all pneumococci identified within this study, compared with the
30.9% of detected pneumococci that are covered by PCV13. Of note
is the considerable proportion of non-encapsulated pneumococci
(11%) that would not be covered by any PCV.
High nasopharyngeal pneumococcal density has been associ-
ated with acute respiratory infections and increased pneumococcal
transmission [27]. The PERCH study found that a pneumococcal
carriage density > 6.9 log10 copies/mL was strongly associated with
microbiologically confirmed pneumococcal pneumonia [28]. In the
current study, we found a median density of 6.98 log10 GE/mL in a
population of infants without pneumonia. This figure is one log
higher than the median density noted in other high carriage den-
sity settings including The Gambia (5.85 log10 GE/mL) and Bangla-
desh (5.99 log10 GE/mL) [28]. In contrast with cross-sectional
carriage surveys conducted in Fiji that found lower pneumococcal
carriage densities in PCV10-vaccinated 12–23 month old children
than in unvaccinated children in the same age group [22], we did
not observe any reduction in pneumococcal carriage density (ei-
ther overall, vaccine types or non-vaccine types) in PCV13-
vaccinated infants compared with unvaccinated children.7
In contrast with the rates of AMR reported by microarray stud-
ies in other lower-middle income countries, including Laos PDR
(70%) and Mongolia (82%) [29,30], the number of pneumococcal
positive samples containing at least one AMR gene was relatively
low within our study (under 20%). While this finding is promising,
the antibiotics used to treat pneumonia in PNG (including amoxi-
cillin, penicillin and gentamicin [23]) were not assessed. Due to
the high prevalence of multiple serotype carriage in our study it
was not practical to examine whether PCV13 serotypes were more
likely to possess resistance genes than non-PCV13 serotypes using
microarray. However, there was no difference in the prevalence of
AMR genes between the PCV13 and unvaccinated cohorts.
There are some limitations to this study, in particular the lim-
ited sample size. Population-based data are required to assess
whether the introduction of PCV13 in PNG has an impact on pneu-
mococcal carriage and more importantly disease at the community
level, including elimination of vaccine serotypes and serotype
replacement. Surveillance of pneumococcal carriage following the
introduction of PCV13 has been undertaken in the EHP, with
results anticipated in 2022. Testing for respiratory viruses would
enhance our results and may provide an explanation for the high
carriage density observed in these infants, as several studies have
shown a positive correlation between respiratory virus detection
and pneumococcal density [31,32]. Given that one-third of vacci-
nated children experienced at least one episode of moderate or
severe pneumonia in their first year of life (and this information
is unknown in the unvaccinated children), sampling at more fre-
quent intervals would allow for assessment of colonisation dynam-
ics surrounding periods of respiratory infection.
Despite these limitations, our results clearly show that PCV13
administration at 1-2-3-months of age had minimal to no impact
on pneumococcal carriage rates, carriage density and diversity in
PNG infants. It is likely that the limited impact of PCV13 on vaccine
type carriage is due to the low prevalence of vaccine serotypes in
K.J. Britton, J.L. Pickering, W.S. Pomat et al. Vaccine xxx (xxxx) xxxthis population and high prevalence of non-vaccine serotypes, as
well as the high rate of pneumococcal acquisition and force of
infection. Further investigation into the social, environmental and
genetic factors predisposing this population to such high pneumo-
coccal carriage is warranted, as is exploration of alternate immuni-
sation schedules and serotype-independent pneumococcal
vaccines.
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